Stockscreener 앱 받기
53.75
0.50%
0.1977
Royalty Pharma Plc 주식(RPRX)의 최신 뉴스
Royalty Pharma PLC $RPRX Shares Bought by Handelsbanken Fonder AB - MarketBeat
Insider Selling: Royalty Pharma (NASDAQ:RPRX) EVP Sells 13,684 Shares of Stock - MarketBeat
Royalty Pharma EVP Marshall Urist sells $721,837 in shares - Investing.com
Royalty Pharma EVP Marshall Urist sells $721,837 in shares By Investing.com - Investing.com Canada
Royalty Pharma (RPRX) EVP Urist sells 13,684 shares in 10b5-1 planned trade - Stock Titan
Royalty Pharma (NASDAQ:RPRX) Hits New 12-Month HighWhat's Next? - MarketBeat
Royalty Pharma stock hits 52-week high at 53.48 USD - Investing.com
Fideuram Intesa Sanpaolo Private Banking S.P.A. Invests $4.92 Million in Royalty Pharma PLC $RPRX - MarketBeat
Thrivent Financial for Lutherans Acquires 22,015 Shares of Royalty Pharma PLC $RPRX - MarketBeat
49,855 Shares in Royalty Pharma PLC $RPRX Acquired by Partners Group Holding AG - MarketBeat
Marathon Asset Management Ltd Has $15 Million Stake in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC $RPRX Shares Acquired by Cullen Frost Bankers Inc. - MarketBeat
RPRX: Royalty financing is rapidly growing, with flexible deals and global expansion fueling future growth - TradingView
Royalty Pharma (RPRX) Benefits from Biotech Funding Gap with Rising Returns and Market Dominance - Insider Monkey
Royalty Pharma plc (RPRX) Investor Outlook: Strong Buy Ratings and Solid Growth Prospects - DirectorsTalk Interviews
Qsemble Capital Management LP Invests $2.88 Million in Royalty Pharma PLC $RPRX - MarketBeat
Commerzbank Aktiengesellschaft FI Invests $982,000 in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC (NASDAQ:RPRX) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Royalty Pharma’s Q1 Earnings Call: Our Top 5 Analyst Questions - Yahoo Finance
Royalty Pharma: Strong Execution, Expanding Pipeline And More Firepower Ahead - Seeking Alpha
Royalty Pharma EVP Urist sells $726,137 in shares - Investing.com UK
Royalty Pharma EVP Urist sells $726,137 in shares By Investing.com - Investing.com Nigeria
Royalty Pharma (RPRX) EVP sells 13,684 shares under 10b5-1 plan - Stock Titan
Rule 10b5-1 sale by Royalty Pharma (RPRX) director Gregory Norden - Stock Titan
Understanding the Setup: (RPRX) and Scalable Risk - Stock Traders Daily
Press Release: Royalty Pharma Declares Second Quarter 2026 Dividend - Moomoo
Royalty Pharma (NASDAQ: RPRX) insider sale notice — 3,045 shares - Stock Titan
[144] Royalty Pharma plc SEC Filing - Stock Titan
Capital International (RPRX) amendment shows 8.8% stake in Royalty Pharma - Stock Titan
Royalty Pharma (RPRX) Valuation Check After Strong Q1 Earnings And Rising Investor Interest - Sahm
Royalty Pharma stock hits 52-week high at 52.16 USD By Investing.com - Investing.com Nigeria
RPRX: Expanding royalty financing, robust pipeline, and strong capital position drive future growth - TradingView
Royalty Pharma stock hits 52-week high at 52.16 USD - Investing.com India
Royalty pharma – funding the next generation of medicines - Livewire Markets
RPRX SEC FilingsRoyalty Pharma Plc 10-K, 10-Q, 8-K Forms - Stock Titan
Income Investors Should Know That Royalty Pharma plc (NASDAQ:RPRX) Goes Ex-Dividend Soon - Yahoo Finance
Hosking Partners LLP Purchases 155,450 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Mitsubishi UFJ Asset Management Co. Ltd. Grows Stock Position in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma plc (RPRX) Stock Analysis: Healthcare Giant with a Promising 16.66% Potential Upside - DirectorsTalk Interviews
C WorldWide Group Holding A S Has $27.07 Million Stake in Royalty Pharma PLC $RPRX - MarketBeat
Accelerated Royalty Deals and Dividend Hike Could Be A Game Changer For Royalty Pharma (RPRX) - simplywall.st
MSN Money - MSN
Royalty Pharma (NASDAQ:RPRX) Upgraded at Wall Street Zen - MarketBeat
Royalty Pharma (NASDAQ:RPRX) Releases Earnings Results, Beats Estimates By $0.08 EPS - MarketBeat
[Form 4] Royalty Pharma plc Insider Trading Activity - Stock Titan
Christopher Hite gains 24,263 Royalty Pharma (RPRX) shares via equity award - Stock Titan
Royalty Pharma (RPRX) EVP gets 18,197-share equity award - Stock Titan
10% Of This Royalty Pharma Insider's Holdings Were Sold - Yahoo Finance
Royalty Pharma raises 2026 portfolio receipts guidance to $3.325B-$3.45B as it scales R&D co-funding - MSN
Royalty Pharma to Present at Upcoming Investor Conferences - Moomoo
Citigroup Raises Royalty Pharma (NASDAQ:RPRX) Price Target to $66.00 - MarketBeat
Royalty Pharma schedules two May healthcare conference webcasts - Stock Titan
JPMorgan Chase & Co. Issues Positive Forecast for Royalty Pharma (NASDAQ:RPRX) Stock Price - MarketBeat
Royalty Pharma to present at upcoming investor conferences - marketscreener.com
Denali Therapeutics (NASDAQ: DNLI) adds cash on AVLAYAH deal despite Q1 loss - Stock Titan
Royalty Pharma Reports Q1 2026 Results: Full Earnings Call Transcript - Sahm
Theravance Biopharma (NASDAQ: TBPH) slashes R&D after ampreloxetine trial miss - Stock Titan
0.76%
1.20%
자본화:
|
볼륨(24시간):